iXCells and Rosebud Biosciences Launch AI-Driven Organoid Collaboration to Predict Personalized Chemotherapy Toxicity

iXCells and partners use patient-specific organoids and AI to predict drug toxicity in heart, liver, and kidney tissues to improve cancer therapy safety.

By: AXL Media

Published: Mar 25, 2026, 5:43 AM EDT

Source: Information for this report was sourced from iXCells Biotechnologies

A Multidisciplinary Alliance for Precision Toxicology

The pharmaceutical landscape is witnessing a strategic shift toward personalized safety profiles as iXCells Biotechnologies joins forces with Rosebud Biosciences, Kantify, and Incite. This international collaboration seeks to address the persistent challenge of off-target chemotherapeutic toxicity, which remains a primary driver of clinical trial attrition. By integrating human cell-based solutions with advanced 3D biology, the partners intend to develop a robust framework for evaluating how novel cancer therapies impact vital organs before they reach the patient bedside.

Reprogramming Patient Cells into Predictive Models

At the core of this initiative is the conversion of peripheral blood mononuclear cells, sourced from a patient diagnosed with liposarcoma, into human induced pluripotent stem cells (hiPSCs). iXCells Biotechnologies leads this foundational stage, leveraging its expertise in cellular reprogramming to create a renewable source of patient-specific genetic material. This process allows the consortium to bypass the limitations of traditional animal testing, providing a biological substrate that more accurately reflects the unique physiological responses of a human subject.

Engineering Miniaturized Organ Systems for Testing

Once the hiPSCs are established, Rosebud Biosciences utilizes its industrialized platform to differentiate these cells into heart, liver, and kidney organoids. These complex 3D structures serve as high-fidelity models of human tissue, allowing researchers to observe drug interactions in a controlled yet biologically relevant environment. The project focuses on these three specific organs because they are the most susceptible to injury during aggressive chemotherapy, often leading to severe secondary health complications for oncology patients.